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Hjo¨rtur H. Jo´nsson2, Jeff Gulcher2, Kari Stefansson2 and Helgi Valdimarsson3
A major susceptibility gene for psoriasis is located in the major histocompatibility complex class I region on
chromosome 6 very close to the HLA-Cw6 gene. We collected a cohort of 1,019 patients with chronic plaque
psoriasis. The patients were typed for HLA-C and HLA-B. A total of 654 (64.2%) were HLA-Cw*0602 positive but
365 (35.8%) carried other HLA-C alleles. We confirmed that HLA-Cw*0602 positive patients have younger age of
onset (17.5 vs 24.3 years, Po1010), higher incidence of guttate and the eruptive type of psoriasis (Po0.0001),
more frequent exacerbations with throat infections (P¼ 0.01), higher incidence of the Koebner’s phenomenon
(P¼ 0.01), and more extensive disease (P¼ 0.03). A striking new finding was a diverging pattern of disease
severity in HLA-Cw*0602 positive and negative patients depending on the age of onset of the disease
(P¼ 0.0006). HLA-Cw*0602 positive women also had more frequent remissions during pregnancy (Po0.0001). All
types of nail changes were, however, more common in the Cw*0602 negative patients (P¼ 0.003) and they more
often had multiple types of nail lesions (Po0.0001). The three ancestral haplotypes of Cw*0602 all conferred an
increase in odds ratio but showed no difference in any of the clinical features studied. Our findings indicate
that the genetic factor on chromosome 6 has a strong influence on the phenotype of the disease, and underline
that differences in clinical features of psoriasis may be to a large extent genetically determined.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disorder that affects
2–3% of Caucasians, and is characterized by T-lymphocyte-
mediated hyperproliferation of keratinocytes (Valdimarsson
et al., 1986; Fry, 1988). The disease has certain distinct but
overlapping clinical phenotypes including chronic plaque
lesions (psoriasis vulgaris), acute and usually self-limiting
guttate attacks, persistent guttate type eruptions, sebo-
psoriasis, pustular lesions, and at least 10% of the patients
also develop arthritis (Espinoza et al., 1992).
Psoriasis is often triggered by infections with b-hemolytic
streptococci (Telfer et al., 1992) and such infections can also
exacerbate chronic plaque psoriasis (Gudjonsson et al.,
2003a, b). The disease also has a strong but complex genetic
background, with a reported concordance of 60–70% in
monozygotic twins (Brandrup et al., 1982). An association
between psoriasis and the HLA-Cw6 antigen was first
reported in 1980 (Tiilikainen et al., 1980) and it was not
until 1997 when the HLA-Cw*0602 allele of the HLA-Cw6
antigen was shown to be associated with type I psoriasis
(Mallon et al., 1997). Approximately 60% of the patients
carry this allele compared to approximately 15% of the
controls. Thus, HLA-Cw*0602 positive individuals have
about 10-fold increased relative risk, whereas homozygotes
for this allele have over 20-fold increased risk of developing
psoriasis (Gudjonsson et al., 2003a, b). It is therefore clear
that the HLA-Cw*0602 allele, or a genetic component very
close by, contributes strongly to the psoriatic predisposition
in about two-thirds of the patients. Accordingly, genetic
studies have consistently shown a strong linkage to a locus on
chromosome 6q that contains the HLA-C alleles (Trembath
et al., 1997; Karason et al., 2005). Several genetic loci have
been reported on other chromosomes but they have not
reached the accepted statistical criteria for genome-wide
significance (LOD score of 3.6; Lander and Kruglyak, 1995),
and some have not been independently confirmed (Enlund
et al., 1999). However, we have recently identified a locus
with a LOD score of 4.2 on chromosome 16 in patients with
psoriatic arthritis and the allele within this locus shows a
preferential paternal transmission (Karason et al., 2003).
Although psoriasis is a common disease that often has a
very strong familial penetrance, the causative genes remain to
be fully elucidated despite an intensive search. It should be
noted in this context that psoriasis patients show a marked
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clinical heterogeneity even within the well-defined and
common phenotype of chronic plaque psoriasis. Twin studies
have indicated that clinical variables such as the age of onset,
disease severity, and some other subphenotypic features of
chronic plaque psoriasis may be genetically determined
(Farber et al., 1974; Brandrup et al., 1982). Yet, analyses of
genetic data have hitherto mostly been based on the
assumption that psoriasis is a homogenous disease entity.
We have recently HLA-B and HLA-C typed and analyzed
clinically 369 patients with chronic plaque psoriasis belong-
ing to 73 multicase families (Gudjonsson et al., 2002). As the
HLA-C alleles are very close to the HLA-B alleles, the HLA-
Cw*0602 allele is in the great majority of cases (B97%)
inherited with one of three HLA-B alleles: B*57, B*37, and
B*13. These three allele combinations are therefore often
referred to as ancestral haplotypes (Jenisch et al., 1998). As
previously reported by others (Henseler and Christophers,
1985; Enerback et al., 1997), we observed that patients who
carry the HLA-Cw*0602 allele have an earlier disease onset,
although there was a marked overlap in this respect with
HLA-Cw*0602 negative patients. However, guttate and
eruptive psoriatic skin lesions were mostly restricted to the
HLA-Cw*0602 positive patients, who also had more ex-
tensive skin lesions and a history of more severe disease
course (Gudjonsson et al., 2002). As the great majority of the
participants in this study had one or more first-degree
relatives who were also affected by psoriasis, we analyzed
650 additional patients who were randomly recruited
regardless of whether or not they had affected relatives. The
study cohort was also expanded in order to increase the
statistical power for analyzing clinical subphenotypes in the
context of disease-modifying genes (Karason et al., 2005).
Thus, in addition to the previously reported differences
between Cw*0602 positive and negative patients who were
all confirmed, some additional Cw*0602-dependent differ-
ences were observed in the extended cohort and potential
clinical differences between patients carrying the three
different HLA-Cw*0602 ancestral haplotypes could also be
evaluated. The detailed clinical assessment of the extended
cohort also proved helpful for localizing genes that are
associated with certain subphenotypes of the disease includ-
ing psoriatic arthritis (Karason et al., 2003, 2005).
RESULTS
We confirmed our previously published findings (Gudjonsson
et al., 2002) in this extended cohort of 1,019 patients that
HLA-Cw*0602 positive patients have an earlier disease onset
than patients who do not carry this allele, although there was
a very marked overlap in this respect between the two
groups, the mean age of onset being 17.5 vs 24.2 years for the
Cw*0602 positive and negative patients, respectively
(Po1010) (Figure 1). As shown in Table 1, we also
confirmed that Cw*0602 positive patients had more extensive
skin involvement (P¼ 0.03), and they reported more often
worsening after throat infections (P¼ 0.002) or lesions
developing at the site of trauma (Koebner’s phenomenon)
(P¼0.01). However, no significant clinical differences were
observed between Cw*0602 positive patients who carried the
three different ancestral haplotypes (Table 1a). A total of 57%
of the HLA-Cw*0602 positive patients and 56% of the HLA-
Cw*0602 negative patients had an affected relative within or
at a genetic distance of 3 meioses.
A striking new finding (Table 1b) was that a partial or total
remission during pregnancy was much more frequently
reported by the Cw*0602 positive women (Po0.0001),
whereas the majority of the women who did not carry this
allele reported that their disease tended to remain unchanged
or got worse while they were pregnant. Furthermore,
diverging patterns of disease severity were observed in
relation to the age of onset depending on whether or not
the patients carried the Cw*0602 allele. Thus, late onset in
Cw*0602 positive patients was associated with relatively
mild disease compared to those with early onset (P¼0.0028,
correlation coefficient (r)¼0.13), whereas the opposite
pattern was observed for patients who did not carry the HLA-
Cw*0602 allele. The interaction between Cw*0602 status
and disease severity was highly significant (analysis of
variance P¼0.0006) (Figure 2). The interaction between
age of onset and Cw*0602 status was also significant
(proportional odds regression P¼ 0.03). This interaction was
independent of family history.
Nail lesions of any type (Table 2) and also multiple types
of nail lesions in the same patient (data not shown) were more
frequently observed in the Cw*0602 negative patients
(P¼0.0008 and Po0.0001, respectively). Nail lesions
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Figure 1. (a) The graph shows comparison of the age of onset distribution of the
three ancestral haplotypes of Cw*0602; HLA-Cw*0602-B*57, HLA-Cw*0602-
B*37, and HLA-Cw*0602-B*13. (b) The graph shows comparison of the age of
onset distribution for the HLA-Cw*0602 positive and negative patients.
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correlated strongly with psoriatic arthritis (Po0.0001), and
this correlation was stronger for nail dystrophy than any other
single type of nail lesions (Table 3). Arthritis was more
common in the Cw*0602 negative patients, but this
difference was not statistically significant.
We have previously reported that heterozygosity for
Cw*0602 is associated with about nine-fold increase in the
relative risk of developing psoriasis compared to 23-fold
increased risk for individuals who are homozygous for this
allele, but the homozygotes did not differ clinically from the
heterozygotes (Gudjonsson et al., 2003a, b). With the higher
number of patients in the extended cohort, it was possible to
compare the clinical features of individuals carrying the three
different ancestral Cw*0602 haplotypes. They all conferred
increased odds ratio (Table 4) and no differences in the age of
onset or clinical features were observed between these three
haplotypes (Table 1a and Figure 1).
DISCUSSION
We have previously observed some striking clinical differ-
ences between 369 HLA-Cw*0602 positive and negative
psoriasis patients with a strong family history (Gudjonsson
Table 1. Clinical comparison of patients carrying the three ancestral haplotypes of Cw*06021 and Cw*0602
positive and negative patients
(a) Patients carrying the three ancestral haplotypes of Cw*0602
Cw*0602-B*57 (n=348) Cw*0602-B*13 (n=127) Cw*0602-B*37 (n=76)
Mean age of disease onset (years) 18.0 18.0 18.3
Guttate onset (%) (n) 10.1 (35) 11.8 (15) 14.5 (11)
Eruptive lesion (%) (n) 20.4 (71) 10.3 (13) 15.8 (12)
Exacerbation during stress (%) (n) 55.2 (192) 55.1 (70) 51.3 (39)
Exacerbation after throat infections (%) (n) 31.3 (109) 30 (38) 36.8 (28)
Koebner’s phenomenon (%) (n) 37.6 (131) 33.1 (42) 32 (24)
Remission during pregnancy2 (%) (n) 42.3 (75) 34.6 (22) 39.5 (15)
Nail changes (%) (n) 34.5 (120) 27.6 (35) 30.3 (23)
(b) Clinical comparison of Cw*0602 positive and negative patients
Cw*0602 pos.3 (n=654) Cw*0602 neg. (n=365) P-value
Mean age of disease onset (years) 17.6 24.2 1010
Guttate onset (%) (n) 11.2 (73) 3.3 (12) 0.0001
Eruptive lesion(%) (n) 17.6 (115) 5.5 (20) 0.0001
Exacerbation during stress (%) (n) 52.3 (342) 49.9 (182) 0.8
Exacerbation after throat infections (%) (n) 30.9 (202) 21 (77) 0.002
Koebner’s phenomenon (%) (n) 35.8 (234) 26.8 (98) 0.01
Remission during pregnancy2 (%) (n) 36.4 (123) 17.7 (29) 0.0001
Nail changes (%) (n) 32.0 (209) 42.5 (155) 0.0008
1There was no statistical difference between any of the groups.
2Percent of those women who had gone through pregnancy.
3Includes the three ancestral haplotypes of HLA-Cw*0602, HLA-Cw*0602 homozygotes and Cw*0602 patients with haplotypes other than the three
ancestral haplotypes.
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Figure 2. The graph shows the association between disease severity and the
mean age of disease onset for the patients belonging to each severity group.
Severity was scored according to Table 5, from 1 (mild) to 4 (very severe). In
Cw*0602 positive patients, an inverse relationship was observed between age
of onset and disease severity; the lower the age of onset, the higher was the
disease severity score. A reverse pattern was observed for the Cw*0602
negative patients; the higher the age of onset, the higher was the disease
severity score.
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et al., 2002). We have now recruited additional 650 patients
irrespective of family history and confirmed that these clinical
differences are not confined to patients with a strong family
history of psoriasis.
A striking new finding in the extended cohort is a
diverging pattern of disease severity in HLA-Cw*0602
positive and negative patients, depending on the age of their
disease onset. Thus, late disease onset in the HLA-Cw*0602
positive patients is associated with relatively mild disease
whereas the reverse was observed for the HLA-Cw*0602
negative patients, and this difference is highly significant
(Figure 1).
Another significant difference between the two groups that
has not been reported before is a much higher remission rate
during pregnancy among the HLA-Cw*0602 positive psor-
iatic women (40 vs 16%, Po0.0001; Table 1). Remission
during pregnancy is common in other autoimmune diseases
like multiple sclerosis (Lorenzi and Ford, 2002) and
rheumatoid arthritis (Olsen and Kovacs, 2002) that, like
psoriasis, are believed to be largely mediated by T helper 1
cells (Lafaille, 1998). Remission during pregnancy has been
reported before (Raychaudhuri et al., 2003), with most of the
patients improving during pregnancy but significant propor-
tion having exacerbation. The difference we find in this
respect between HLA-Cw*0602 positive and negative pa-
tients indicates that this phenomenon may be to a large extent
genetically determined.
Our findings confirm the observation, first reported by
Henseler and Christophers (1985), that HLA-Cw*0602
positive psoriasis patients have an earlier disease onset than
those who are HLA-Cw*0602 negative. However, the two
groups show a very marked overlap in this respect, and we
could not detect a second peak of disease onset after the age
of 40 years. Furthermore, many of the HLA-Cw*0602
negative patients had a strong family history of psoriasis,
and this also applied to a significant proportion of HLA-
Cw*0602 negative patients with late disease onset (440
years). The classification of psoriasis into type 1 and type 2,
which is frequently quoted, was based on the following
criteria: type 1 patients with disease onset before the age of
40 years, at least one first-degree relative affected, and mostly
HLA-Cw*0602 positive; type 2 patients with disease onset at
the age of 40 years or later, lack of family history, and normal
frequency of the HLA-Cw*0602 allele. Our findings indicate
that classification of patients according to these criteria is
probably not useful for analyzing epidemiological or genetic
data because of an extensive overlap. Classification based on
whether or not patients carry the HLA-Cw*0602 allele is
probably more helpful at least until the genetic heterogeneity
of psoriasis has been elucidated further (Karason et al., 2005).
Genetic linkage scan have consistently showed that a
major gene for psoriasis is located on chromosome 6 in the
MHC class I region very close to the HLA-Cw*0602 gene
(Trembath et al., 1997; Jenisch et al., 1998; Bowcock and
Cookson, 2004) if not being the HLA-Cw*0602 allele itself.
We have obtained data indicating that HLA-Cw*0602 allele
may directly participate in the pathogenesis of psoriasis in
those patients who carry this allele (Johnston et al., 2004).
Recent observation that individuals who carry HLA-Cw*0602
on different ancestral haplotypes have significant differences
in relative risk (Jenisch et al., 1998) does not, in our opinion,
seriously challenge this proposition. First, the lower risk HLA-
Cw*0602 haplotype could be a part of an extended haplotype
carrying HLA-class II allele(s) that are less effective in
presenting psoriasis antigen(s) to CD4þ T cells than the
HLA-class II alleles that tend to be present on the extended
Table 2. Frequency of nail lesions in Cw*0602 positive
and negative patients
Cw*0602
positive
(n=654)
Cw*0602
negative
(n=365) P-value
Pits (%) (n) 15.6 (102) 26.4 (96) 0.0001
Onycholysis (%) (n) 28.0 (183) 37.0 (135) 0.004
Subungual
hyperkeratosis (%) (n)
9.2 (60) 15.9 (58) 0.002
Dystrophy (%) (n) 4.6 (30) 10.9 (40) 0.0002
Table 3. Association between HLA-C carriages, nail
lesions, and arthritis
Frequency of
Cw*0602
positive with
arthritis
Frequency of
Cw*0602
negative with
arthritis P-value
No nail lesions (%)
(n=644)
9.7 (50 of 438) 14.1 (23 of 206) 1.0
All types of nail
lesions except
dystrophy (%)
(n=302)1
19 (35 of 184) 25.7 (29 of 118) 0.25
Nail dystrophy (%)
(n=64)2
29.7 (8 of 27) 40.6 (15 of 37) 0.43
1Psoriatic arthritis was significantly more common in patients with nail
changes, compared to patients without nail changes, Po0.0001.
2Psoriatic arthritis was significantly more common in patients with nail
dystrophy compared to patients with other types of psoriatic nail changes,
P=0.015.
Table 4. Odds ratio of the ancestral haplotypes
Frequency in
psoriasis patients
(n=1,019)
Frequency in
controls
(n=533) Odds ratio
Cw*0602-B57 34.8% 6.4% 7.85
Cw*0602-B13 13.5% 3.2% 4.75
Cw*0602-B37 7.7% 4.9% 1.62
Their associations with psoriasis gave P-values of 1037 for HLA-
Cw*0602-B*57, 1012 for HLA-Cw*0602-B*13, and 104 for HLA-
Cw*0602-B*37.
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higher risk haplotypes. Second, the three extended haplo-
types could carry different alleles of the genes in the HLA-
class III region that are known to code for components that
can modify immune responses, including tumor necrosis
factor-a and transporter associated with antigen presentation.
Thus, the two higher risk extended haplotypes might carry
alleles that enhance the immune mechanisms that operate in
psoriasis.
We conclude that psoriasis is an immunological disease
with heterogenous genetic and pathogenic background, and
that this heterogeneity is to a considerable extent associated
with different clinical phenotypes. A careful documentation
of clinical features may therefore be of critical importance for
elucidating the etiopathogenesis of the disease.
MATERIALS AND METHODS
Recruitment and clinical evaluation of patients
The additional 650 patients, mostly recruited by the Icelandic
Psoriasis Foundation (SPOEX), were recruited from the same
population and assessed as previously described by the same
physicians (H.V. and J.E.G.) who also examined the original cohort
of 369 patients (Gudjonsson et al., 2002). Briefly, the patients had to
have at least one unequivocal psoriatic plaque at the time of the
examination to be included in the study. The clinical information
was recorded in a structured manner and family history was
obtained for each patient and recorded as positive if a second
degree or a closer relative had psoriasis. All available relatives with
potential psoriasis were also evaluated. We used our genealogical
database to evaluate the relatedness of the patients. Family history
was defined as positive if patient had an affected relative at or within
3 meioses. Clinical data included age and site of onset, disease
course and severity, treatments, and the effects of environmental
factors that have been reported to influence the disease course. The
distribution and the size of the plaques were recorded and disease
severity scored from 1 to 4 for each patient according to the criteria
summarized in Table 5. Scoring of disease severity was based not
only on the extent and inflammatory activity of the plaques and
papules at the time of the examination, but also on the treatment that
the patient had been given or was receiving at the time of the
examination. However, arthritis was not included in the severity
score. Four types of psoriatic nail changes were recorded, namely
pitting, onycholysis, subungual hyperkeratosis, and dystrophy. Nail
changes were only recorded for the fingers, because of high
frequency of fungal infections in toe-nails (Gudnadottir et al.,
1999), which often can mimic psoriatic nail changes. Patients with
seborrhoeic or pustular psoriasis, or only a history of guttate
psoriasis, were not included if they did not have any typical chronic
psoriatic plaques at the time of the examination. Patients were
recorded as having psoriatic arthritis only if they had been diagnosed
and treated for psoriatic arthritis by a rheumatologist. The clinical
assessment was carried out and recorded before the patients were
typed for HLA-B and HLA-C alleles.
The study was approved by the Ethical Committee of Landspitali
University Hospital in Reykjavik. Informed consent was obtained
from all participants examined in the study. The study was
conducted according to the guidelines of the Declaration of
Helsinki.
HLA-C and HLA-B typing
The patients were typed by PCR-based method for all known HLA-C
alleles with a Dynal HLA-C SSP low-resolution kit (Dynal biotech
Ltd, Merseyside, UK), as instructed by the manufacturer. HLA-B
typing was carried out for HLA-B with a Dynal HLA-B SSO kit (Dynal
biotech Ltd, Merseyside, UK) In addition, 533 randomly recruited
Icelandic controls were typed for HLA-C and HLA-B. HLA-B*13 and
HLA-B*37 occurs in Caucasians almost without exception with
HLA-Cw*0602 on one haplotype, and in our study population the
same applied to HLA-B*57.
Statistical analysis
Differences between the groups in the age of onset and disease
severity were analyzed by the Mann–Whitney U-test, but the Fisher’s
exact test was used for comparing the frequencies of variables
between the groups. Odds ratio was calculated from allele
frequencies in the patients and the controls (Table 4) assuming
Hardy–Weinberg equilibrium. Correlation coefficients and P-values
were calculated by the Spearman’s rank sum test. To investigate the
relationship between Cw*0602 status, disease severity, and age of
onset, we performed a two-way analysis of variance with interaction,
where we treated disease severity and Cw*0602 as the independent
variables and the age of onset as the outcome. To further investigate
this relationship, we performed proportional odds regression with
disease severity as the dependent variable and Cw*602 status and
the dichotomized age of onset (dichotomized at the median age of
Table 5. Disease severity scoring
Very severe (4) Severe (3) Moderate (2) Mild (1)
K 450% body area K 20–50% body area K 5–20% body area K o5% body area
or or or K No treatment
K Continuous oral treatment K Intermittent oral treatment K Guttate disease or
or or K Periodical local treatment
K PUVA treatment K UVB treatment
or or
K Extensive disabling lesions in hands or feet K Extensive local treatment
Score values ranged from 1 to 4.
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onset) as the independent variables. This was performed with and
without an interaction term and a likelihood ratio test performed for
the significance of the interaction.
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